

**Reduction in Maximum Retail Price (MRP) of Anti-Cancer Medicines
w.e.f 9th November 2026.**

S No.	Drug	Brand Name	Strength	Dosage Form	Pack Size	OLD MRP (Incl. GST Till 08-11-2026)	NEW MRP (Incl. GST from 09-11-2026)
1	Abiraterone Acetate 250Mg	Abirakast 250	250Mg	Tab	120	18281.25	3898.00
2	Abiraterone Acetate 500Mg	Abirakast 500	500Mg	Tab	60	18750.00	4571.00
3	Acalabrutinib 100Mg	Acalakast 100	100Mg	Tab	30	13312.50	7457.00
4	Axitinib 5Mg	Inlybest 5	5Mg	Tab	28	3740.63	1514.00
5	Cabozantinib 20Mg	Cabozer 20	20Mg	Tab	30	4500.00	2756.00
6	Cabozantinib 40Mg	Cabozer 40	40Mg	Tab	30	8437.50	2852.00
7	Cabozantinib 60Mg	Cabozer 60	60Mg	Tab	30	12656.25	3508.00
8	Crizotinib 250Mg	Crizokast	250Mg	Caps	60	25000.00	13428.00
9	Cytarabine 1000Mg	Cytarzer 1000	1000Mg	Vial	1	1200.00	270.00
10	Dasatinib 50Mg	Dasakast 50	50Mg	Tab	60	6093.75	1425.00
11	Dasatinib 70Mg	Dasakast 70	70Mg	Tab	60	7968.75	1850.00
12	Enzalutamide 160Mg	Indenza 160	160Mg	Tab	7	5812.50	3010.00
13	Enzalutamide 40Mg	Indenza 40	40Mg	Caps	28	10312.50	2425.00
14	Fulvestrant 250Mg/5ml	Fulvekast	250Mg/5ml	PFS	1	16875.00	2821.00
15	Lapatinib 250Mg	Lapakast 250	250Mg	Tab	30	6100.00	2700.00
16	Lenvatinib 10Mg	Lenvakast 10	10Mg	Caps	30	8985.94	3646.00
17	Lenvatinib 4Mg	Lenvakast 4	4Mg	Caps	30	4485.94	1492.00
18	Mitomycin 10Mg	Mitomycin 10	10Mg	Vial	1	388.13	468.00
19	Olaparib 150Mg	Olabor 150	150Mg	Tab	120	42656.25	14815.00
20	Olaparib 150Mg	Olabor 150	150Mg	Tab	30	10781.25	4122.00
21	Palbociclib 125Mg	Palbocib 125	125Mg	Caps	21	7125.00	2569.00
22	Pazopanib 200Mg	Pazokast 200	200Mg	Tab	30	1968.75	1349.00
23	Pazopanib 400Mg	Pazokast 400	400Mg	Tab	30	3562.50	2609.00
24	Pemetrexed 500Mg	Pemeaxis 500	500Mg	Vial	1	3816.56	1747.00
25	Sunitinib Malate 25Mg	Sutekast 25	25Mg	Caps	28	3700.00	1714.00
26	Sunitinib Malate 50Mg	Sutekast 50	50Mg	Caps	28	7180.00	3257.00

Note: Above mentioned Revised MRP's are in accordance with recent NPPA Notification ref no. S.O. 5690(E). - Dated 17 October 2026



Aprazer Healthcare Pvt. Ltd.

Corporate Office: Aprazer House, 1E/20, Jhandewalan Extension, New Delhi-110055, India
 Plot no. C-177, UGF, Naraina Industrial Area , Phase -1, South West Delhi, New Delhi - 110028, India
 Plot no. 43, Sector 1B, IIE, SIDCUL Haridwar Uttarakhand - 249403, India
 Ph.: +91 11 41613355 CIN No.: U51909DL2017PTC326040

IMPORTANT CIRCULAR TO TRADE PARTNERS

Date: 30 October 2026

To,
All Stockists, Distributors and Retailers

Subject: Implementation of NPPA-mandated trade margin and MRP revisions for specified non-scheduled anti-cancer products

Reference: NPPA Order No. S.O. 5690(E) dated 17 October 2026.

Dear Trade Partner,

We wish to inform you that the National Pharmaceutical Pricing Authority (NPPA), through the order cited above, has prescribed a trade-margin framework for certain non-scheduled anti-cancer formulations. In accordance with the said order, manufacturers are required to align the prices of products falling within its scope with applicable regulatory provisions.


Following a review of the products marketed by Aprazer Healthcare Pvt. Ltd., the revised prices for products covered by the order are being communicated through the accompanying price list. These prices are scheduled to take effect from 09 November 2026, subject to the scope and requirements of the applicable NPPA order and DPCO, 2013.

Please arrange for the following measures within your respective operations:

1. **Price list review.** Check the enclosed list and identify the Aprazer products for which revised MRPs have been specified.
2. **System updates.** Revise the relevant product price masters, ERP records and billing configurations in time for the effective date.
3. **Invoices from the effective date.** Ensure that transactions invoiced on or after 09 November 2026 reflect the applicable revised pricing.
4. **Trade-channel communication.** Share the updated price information with relevant retailers and downstream channel partners so that the revised prices are implemented consistently.
5. **Stock and consumer pricing.** Handle packs bearing the earlier printed MRP in accordance with applicable NPPA directions and DPCO, 2013. The selling price to consumers must not exceed the legally applicable MRP.
6. **Price-list display.** Display the applicable price list or supplementary price list at the business premises wherever required under applicable regulations.

Action Required

- Examine the enclosed revised price list and confirm which products are affected.
- Make the necessary changes to ERP, billing software and product price masters before the implementation date.
- Ensure that invoices issued on or after 09 November 2026 carry the applicable revised prices.
- Inform all relevant retailers and downstream trade partners of the revised pricing and its effective date.
- Retain the updated price list for reference and ensure implementation in accordance with the applicable NPPA order and DPCO, 2013.



Aprazer Healthcare Pvt. Ltd.

Corporate Office: Aprazer House, 1E/20, Jhandewalan Extension, New Delhi-110055, India
Plot no. C-177, UGF, Naraina Industrial Area , Phase -1, South West Delhi, New Delhi - 110028, India
Plot no. 43, Sector 1B, IIE, SIDCUL Haridwar Uttarakhand - 249403, India
Ph.: +91 11 41613355 CIN No.: U51909DL2017PTC326040

Your timely attention is requested to ensure a smooth transition to the revised pricing. Please circulate this communication to the concerned personnel and retain the updated price list for reference and implementation.

This circular is issued for information and necessary action in relation to the above-referenced regulatory order. For any product-specific clarification, please contact your designated Aprazer Healthcare representative.

Thank you for your continued cooperation.

Yours sincerely,

For APRAZER HEALTHCARE PVT. LTD.



Authorised Signatory

Enclosures:

1. Applicable Revised MRP list.
2. Copy of NPPA Order No. S.O. 5690(E) dated 17 October 2026.

Aprazer Healthcare Pvt. Ltd.

Corporate Office: Aprazer House, 1E/20, Jhandewalan Extension, New Delhi-110055, India
Plot no. C-177, UGF, Naraina Industrial Area , Phase -1, South West Delhi, New Delhi - 110028, India
Plot no. 43, Sector 1B, IIE, SIDCUL Haridwar Uttarakhand - 249403, India
Ph.: +91 11 41613355 CIN No.: U51909DL2017PTC326040

Annexure 1
(Applicable Revised MRP List)



Aprazer Healthcare Pvt. Ltd.

Corporate Office: Aprazer House, 1E/20, Jhandewalan Extension, New Delhi-110055, India
Plot no. C-177, UGF, Naraina Industrial Area , Phase -1, South West Delhi, New Delhi - 110028, India
Plot no. 43, Sector 1B, IIE, SIDCUL Haridwar Uttarakhand - 249403, India
Ph.: +91 11 41613355 CIN No.: U51909DL2017PTC326040